Cargando…

Incidence, prevalence, and comorbidities of juvenile idiopathic arthritis in Germany: a retrospective observational cohort health claims database study

BACKGROUND: Juvenile idiopathic arthritis (JIA) describes heterogenous categories of chronic inflammatory rheumatic conditions of unknown origin in children and adolescents. Epidemiological data in the literature vary, depending on geographic location, ethnicity and the case definition used. We eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horneff, Gerd, Borchert, Julia, Heinrich, Ria, Kock, Simon, Klaus, Pascal, Dally, Heike, Hagemann, Christine, Diesing, Joanna, Schönfelder, Tonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670409/ https://www.ncbi.nlm.nih.gov/pubmed/36384690 http://dx.doi.org/10.1186/s12969-022-00755-x

Ejemplares similares

Predictors of response to methotrexate in juvenile idiopathic arthritis
por: Albarouni, Mohamed, et al.
Publicado: (2014)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany
por: Christensen, Stefan, et al.
Publicado: (2019)

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
por: Bakry, Reima, et al.
Publicado: (2022)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
por: Heiligenhaus, Arnd, et al.
Publicado: (2020)

Prevalence and risk factors of depressive symptoms in children and adolescents with juvenile idiopathic arthritis
por: Roemer, Johanna, et al.
Publicado: (2023)

Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany
por: Hinze, Claas H., et al.
Publicado: (2018)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study
por: Hospach, Toni, et al.
Publicado: (2014)

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
por: Horneff, Gerd, et al.
Publicado: (2023)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2017)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis
por: Mäder, Melanie, et al.
Publicado: (2023)

Lichen planus in Germany – epidemiology, treatment, and comorbidity. A retrospective claims data analysis
por: Schruf, Eva, et al.
Publicado: (2022)

Survival and comorbidities in lung cancer patients: Evidence from administrative claims data in Germany
por: HERNANDEZ, DIEGO, et al.
Publicado: (2023)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Non-Rheumatic Chronic Comorbidities in Children with Juvenile Idiopathic Arthritis
por: Haşlak, Fatih, et al.
Publicado: (2023)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis
por: STÄNDER, Sonja, et al.
Publicado: (2020)

Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study
por: Francis-Sedlak, Megan, et al.
Publicado: (2020)

Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
por: Thiele, Franz, et al.
Publicado: (2021)

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, Gregor, et al.
Publicado: (2012)

Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis
por: Schmeling, H, et al.
Publicado: (2008)

Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Neuropsychiatric comorbidities in Huntington’s and Parkinson’s Disease: A United States claims database analysis
por: Ishihara, Lianna, et al.
Publicado: (2020)

Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
por: Montag, Laura J, et al.
Publicado: (2022)

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
por: Kondoh, Yasuhiro, et al.
Publicado: (2022)

Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis
por: Hagenström, Kristina, et al.
Publicado: (2021)

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
por: Kudela, Holger, et al.
Publicado: (2019)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
por: Hata, Takeo, et al.
Publicado: (2022)

Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial
por: Ruperto, Nicola, et al.
Publicado: (2014)

Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013
por: Haas, Jennifer, et al.
Publicado: (2015)

Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France
por: Pourcher, Valérie, et al.
Publicado: (2020)

Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: A Health Insurance Claims Database Analysis
por: REINHARDT, Maximilian, et al.
Publicado: (2021)

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tjevcsntssd5a7vccvuqvoj0eu